Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEL-SCI Corp. Receives Approval from North Mississippi Health Services’ Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Date : 09/13/2010 @ 9:45AM
Source : Business Wire
Stock : CEL-SCI Corporation (CVM)
http://ih.advfn.com/p.php?pid=nmona&article=44343523&symbol=CVM
CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received approval from the North Mississippi Health Services (“North Mississippi”) Institutional Review Board (“IRB”) to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
CEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi is the first site in the United States to approve enrollment of subjects. CEL-SCI’s trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted. CEL-SCI plans to announce additional site approvals and country approvals as they become known.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects’ tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
About North Mississippi Health Services
North Mississippi Health Services (NMHS) is a diversified regional health care organization, which serves 24 counties in north Mississippi and northwest Alabama from headquarters in Tupelo, Mississippi. The NMHS organization covers a broad range of acute diagnostic and therapeutic services, offered through North Mississippi Medical Center in Tupelo; a community hospital system with locations in Eupora, Iuka, Pontotoc, West Point, Miss. and Hamilton, Alabama, North Mississippi Medical Clinics, a regional network of more than 30 primary and specialty clinics; and nursing homes. NMHS has an IRB that meets monthly. The NMHS IRB members include doctors, nurses, pharmacists, social workers, a lawyer, risk manager, and community members. This group reviews the science and ethics of the research. Their objective is to assess the risks and benefits to subjects involved in the study. The NMHS IRB has the authority to approve, require modification to, or disapprove all research activities that involve an NMHS investigator, facility, or patient group. Following initial approval, the IRB conducts periodic reviews of such research. In most instances, in order to approve research, an IRB must determine that specified criteria have been satisfied. Among these criteria, an IRB must determine that, when appropriate, the research protocol includes "adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data."
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery. A pivotal Phase III clinical trial with Multikine in head and neck cancer is expected to start in the second half of 2010.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
PDL BioPharma Announces Conversion Rate Adjustment for 2.00% Convertible Senior Notes Due February 15, 2012
Date : 09/13/2010 @ 7:00AM
Source : PR Newswire
Stock : Pdl Biopharma (MM) (PDLI)
http://ih.advfn.com/p.php?pid=nmona&article=44339823&symbol=N^PDLI
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.
The conversion rate for the 2012 Notes, as adjusted, is 140.571 shares of common stock per $1,000 principal amount or $7.11 per share. The conversion rate for the 2012 Notes was previously 128.318 shares of common stock per $1,000 principal amount of the 2012 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of September 13, 2010 for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Forward-looking Statements
The foregoing statements regarding PDL's intentions with respect to the cash special dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to pay the special dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.
SOURCE PDL BioPharma, Inc.
Company Overview Presentation - August 2010
http://pdl.com/wp-content/uploads/2010/07/PDL_BioPharma_Company_Overview_August_2010.pdf
Upcoming Events - September 2010
Rodman & Renshaw 12th Annual Healthcare Conference
September 14, 2010, 5:45 p.m. - 6:10 p.m. Eastern
The New York Palace Hotel, New York City
http://www.reprosrx.com/investors_events.php
Idera Pharmaceuticals to Present at Upcoming Investor Conferences
Date : 09/08/2010 @ 4:05PM
Source : Business Wire
Stock : Idera Pharmaceuticals, Inc. (IDRA)
http://ih.advfn.com/p.php?pid=nmona&article=44294120&symbol=N^IDRA
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:
* The Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15 at 10:50 a.m. ET at the New York Palace Hotel, New York City
* The UBS Global Life Sciences Conference on Monday, September 20 at 7:30 a.m. ET at the Grand Hyatt New York Hotel in New York City
The live audio webcast presentations will be available in the Investor section of the company’s website at www.iderapharma.com. Archived replays will also be available on the company’s site for two weeks following the events. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The company’s proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Idera’s pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
Almaden Minerals discloses intent of raising $7.5 mln for ongoing exploration and development activities on Almaden's Mexico projects; placement consists of 3 mln shares at $2.5
shareBriefing.com(Fri, Sep 10)
http://finance.yahoo.com/marketupdate/inplay#aau
http://finance.yahoo.com/q?s=aau
Corporate Presentation - August 2010
http://files.shareholder.com/downloads/SUNP/1010871122x0x363037/BB8E4AA5-CF12-4286-B804-F7946B7D6663/Corporate_Presentation.pdf
NewCardio Announces Publication by Heart Rhythm of Cardio3KG Clinical Study to Improve Acute Cardiac Diagnosis
Date : 09/08/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=44285757&symbol=NB^NWCI
NewCardio (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that a clinical study of the Cardio3KG™ in acute cardiac diagnosis has been published in the August 2010 issue of the peer-reviewed journal, Heart Rhythm, the official journal of the Heart Rhythm Society. The study, entitled "Vectorcardiographic and Electrocardiographic Criteria to Distinguish New and Old Left Bundle Branch Block," was led by Alexei Shvilkin, MD, PhD, Peter Zimetbaum, MD, Kalon Ho, MD, and Mark Josephson, MD, from the Cardiology Division at Beth Israel Deaconess Medical Center and Harvard Clinical Research Institute, Boston, in collaboration with Ihor Gussak MD, PhD, Bosko Bojovic PhD, and Branislav Vajdic, PhD, from NewCardio.
Patients in Emergency Departments (ED) with suspected myocardial infarction (MI), commonly referred to as a heart attack, frequently have a diffuse 12-lead ECG abnormality known as Left Bundle Branch Block (LBBB). Unfortunately, this abnormality makes it difficult or impossible to "read" the ECG for signs of an acute heart attack. Because of this uncertainty, the great majority of LBBB patients are taken directly for invasive interventional procedures. In most such patients, however, the LBBB abnormality is an old and stable finding unrelated to the patient's current symptoms, and the procedures expose the patient to unnecessary risk and discomfort, as well as adding to healthcare costs. Thus, a fast, reliable and inexpensive way to distinguish patients with "old" LBBB from patients with "new" LBBB is needed.
Dr. Shvilkin and colleagues obtained ECG data from 39 patients with new LBBB and 1760 patients with old LBBB, and used NewCardio's Cardio3KG suite of 3D-based ECG analysis algorithms to identify a novel Cardio3KG marker called the QRS-T Loop ratio. This allowed highly accurate discrimination between new and old LBBB (100% sensitive and 96% specific for correctly assigning LBBB tracings to the "new" or "old" category). This important advance is expected to provide a cost-effective solution to a long-standing and notoriously difficult diagnostic dilemma in acute MI diagnosis. Moreover, because the Cardio3KG uses standard 12-lead ECG input, its analytical results are available in minutes and require no change in standard ED practices or special training of the ED staff.
Dr. Shvilkin, the study's Principal Investigator, commented: "We believe these study results have substantial clinical significance. The ability of Cardio3KG to identify old LBBB will help reduce unnecessary invasive procedures and lower the overall cost of medical care. On the other hand, the accurate identification of new LBBB by Cardio3KG will reinforce the need for aggressive management and urgent coronary intervention, and may thereby improve long-term clinical outcomes for acute MI patients."
Dr. Gussak, NewCardio's Chief Medical Officer and a study co-investigator, commented: "The paper makes a major and exciting contribution to acute MI diagnosis. Our clinical studies to date have shown a substantial improvement in sensitivity for diagnosing a heart attack. The latest results show that Cardio3KG accurately identifies new LBBB, adding to the diagnostic power of this solution. We are very fortunate to work with Dr. Shvilkin and his Harvard colleagues on this and other Cardio3KG studies. Their work represents truly innovative and important contributions, and we look forward to many more."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio
Unilife to Participate in Three Investor Conferences
Date : 09/07/2010 @ 8:00AM
Source : PR Newswire
Stock : Unilife (MM) (UNIS)
http://ih.advfn.com/p.php?pid=nmona&article=44269354&symbol=N^UNIS
Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that its Chief Executive Officer, Alan Shortall, will be presenting at three upcoming investor conferences taking place in New York and Boston.
* On Monday, September 13, Mr. Shortall will present at the Rodman and Renshaw Annual Global Investment Conference in New York at 10:25 a.m. EDT.
* On Wednesday, September 15, Mr. Shortall will present at the Stifel Nicolaus Healthcare Conference in Boston at 8:35 a.m. EDT.
* On Monday, September 20, Mr. Shortall will present at the UBS Global Life Sciences Conference in New York at 4:00 p.m. EDT.
Each of the conference presentations will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://ir.unilife.com/events.cfm. An archive of each event will also be available for those unable to listen live.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.
Antisoma's phase III trial of AS1413 completes patient enrolment
Date : 09/08/2010 @ 2:00AM
Source : UK Regulatory (RNS & others)
Stock : Antisoma (ASM)
http://ih.advfn.com/p.php?pid=nmona&article=44279511&symbol=L^ASM
London, UK, and Cambridge, MA: 8 September 2010 - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) announces that the ACCEDE phase III trial of AS1413
(amonafide L-malate) in secondary acute myeloid leukaemia (secondary AML) is now
fully enrolled. Data from the trial are expected in the first half of 2011, with
filings for marketing authorisations to follow if these are positive.
ACCEDE is a single pivotal, randomised, controlled trial in which a regimen of
AS1413 and cytarabine is compared with standard AML remission-induction therapy
of daunorubicin and cytarabine ('7+3'). The primary endpoint of the study is the
rate of complete remission with or without recovery of normal blood counts.
Recruitment into the study has been rapid, especially over the past year.
Over 420 patients from 22 countries have been included, making it the largest
prospective trial ever conducted in patients with secondary AML.
Secondary AML is a significant subgroup of AML that develops from prior
myelodysplastic syndrome (MDS) or follows treatment of another cancer with
chemotherapy or radiotherapy. The disease is often multi-drug resistant and
responds poorly to currently available therapies. A key feature of AS1413, and a
potential advantage over many current AML treatments, is the drug's ability to
evade multi-drug resistance mechanisms.
Professor Richard Stone, MD, Director of the Adult Leukemia Program at the
Dana-Farber Cancer Institute, Boston, and one of the leading investigators in
the AS1413 phase III trial, said: "There is a great need for new treatment
options for patients with poor-risk AML, such as the secondary AML patients
included in the ACCEDE trial. It will be fascinating to see if AS1413 can
deliver on the promise suggested by earlier studies."
Glyn Edwards, CEO of Antisoma, said: "Completion of enrolment in the phase III
trial is a critical milestone in the development of AS1413, and puts us on track
to see the outcome in the near future. I would like to thank all the patients
and physicians who have joined with us in seeking to improve the treatment of
secondary AML."
AS1413 has orphan drug status in both the U.S. and the E.U. for the treatment of
AML and recently received Fast Track status from the U.S. FDA for the treatment
of secondary AML.
Enquiries:
Glyn Edwards, CEO
Daniel Elger, VP Marketing & Communications +44 (0)20 3249 2100
Antisoma plc
Mark Court/Lisa Baderoon/Catherine Breen +44 (0)20 7466 5000
Buchanan Communications
Except for the historical information presented, certain matters discussed in
this announcement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.
About AS1413 (amonafide L-malate)
AS1413 (amonafide L-malate) was added to Antisoma's pipeline through the
acquisition of Xanthus Pharmaceuticals, Inc. in June 2008. AS1413 is a novel DNA
intercalator that induces apoptotic signalling by blocking topoisomerase II
binding to DNA. This differs from the action of classical topoisomerase II
inhibitors, which induce apoptosis by causing extensive DNA damage. A further
distinctive feature of AS1413 is its ability to evade Pgp and related
transporters responsible for multi-drug resistance (MDR).
A pivotal phase III trial (ACCEDE) is evaluating AS1413 as a treatment for
secondary AML, a condition often associated with MDR and in which outcomes with
currently available treatments are poor. The trial was designed to screen 450
patients in order to enrol 420 eligible patients. Enrolment is now completed.
Data are expected in the first half of 2011 after all patients have completed
treatment under the trial protocol and findings have been collated and analysed.
An earlier phase II trial showed a complete remission rate of 39% in patients
with secondary AML, a finding that compares favourably with data from two
previous co-operative group studies in which similar patients were treated with
standard anthracycline plus cytarabine regimens.
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the U.K. and the U.S. Please visitwww.antisoma.com for further information
about Antisoma.
[HUG#1443027]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Antisoma plc via Thomson Reuters ONE
Name Change to Apricus Biosciences - ( APRI )
NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences
Date : 09/10/2010 @ 4:31PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&article=44327838&symbol=NEXM
NexMed, Inc. (Nasdaq:NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced the results of its Special Meeting of Stockholders, held today, Friday, September 10, 2010.
At the Special Meeting, the Stockholders of the Company approved, by an affirmative majority vote, to change the name of the Company from NexMed, Inc. to Apricus Biosciences, Inc. (“Apricus Bio”), effective September 10, 2010. The name change was brought on to reflect the broader focus of the Company’s development programs. The Company’s common stock will commence trading under the symbol, NASDAQ: APRI, effective at the open of the market on Tuesday, September 14, 2010.
Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, commented, “Beginning with the acquisition of Bio-Quant by NexMed in late 2009, we have undertaken a number of positive changes that are expected to reshape the Company over the long-term. In particular, we have expanded our product pipeline, re-energized the development of the NexACT technology as a drug delivery platform and have begun active licensing efforts for both proprietary programs, as well as third party programs enhanced with the NexACT technology. Additionally, we have leveraged Bio-Quant’s CRO capabilities to help advance new applications for NexACT. The rebranding of the Company at this time is part of our broader effort to alert potential development partners and the investment community of our new business model.”
In connection with the Company’s name change, management expects to launch its new website, http://www.apricusbio.com on Tuesday, September 14, 2010.
In addition, the Stockholders approved, by an affirmative majority vote, to increase the number of shares of Common Stock authorized for issuance by the Company from 18,000,000 shares to 75,000,000 shares.
About Apricus Biosciences
Backed by a solid, revenue generating CRO business, Bio-Quant, Inc., and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on the Company and its subsidiaries, visit http://www.nexmed.com.
PDL BioPharma ( PDLI ) - Special Dividend
PDL BioPharma Announces Ex-Dividend Date of September 13 for Special Dividend
Press Release Source: PDL BioPharma, Inc.
Thursday September 9, 2010, 7:00 am EDT
http://finance.yahoo.com/news/PDL-BioPharma-Announces-prnews-144309247.html?x=0&.v=1
INCLINE VILLAGE, Nev., Sept. 9 /PRNewswire-FirstCall/ --
PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced that NASDAQ has established September 13, 2010 as the ex-dividend date for its second of two special dividends to stockholders declared by the Board of Directors on January 27, 2010. The dividend of $0.50 per share will be paid on October 1, 2010 to all stockholders of record on September 15, 2010.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com
###############################################################################################
PDL BioPharma to Present at Upcoming Investor Conferences
Press Release Source: PDL BioPharma, Inc.
Wednesday September 8, 2010, 7:00 am EDT
http://finance.yahoo.com/news/PDL-BioPharma-to-Present-at-prnews-931969264.html?x=0&.v=1
INCLINE VILLAGE, Nev., Sept. 8 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced that John P. McLaughlin, the Company's president and chief executive officer, will present at the following upcoming conferences.
Rodman & Renshaw Annual Global Investment Conference
Monday, September 13, 2010
4:30 p.m. Eastern time
New York City
Morgan Stanley Global Healthcare Unplugged Conference
Tuesday, September 14, 2010
3:55 p.m. Eastern time
New York City
Both presentations will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.
################################################################################################
Coverage initiated on PDL BioPharma by RBC Capital Mkts
Upgrades & Downgrades History
http://finance.yahoo.com/q/ud?s=PDLI
10-Sep-10 Initiated RBC Capital Mkts Sector Perform $6
http://www.finviz.com/quote.ashx?t=pdli&ty=c&ta=0&p=d
PDL BioPharma ( PDLI ) - Special Dividend
PDL BioPharma Announces Ex-Dividend Date of September 13 for Special Dividend
Press Release Source: PDL BioPharma, Inc.
Thursday September 9, 2010, 7:00 am EDT
http://finance.yahoo.com/news/PDL-BioPharma-Announces-prnews-144309247.html?x=0&.v=1
INCLINE VILLAGE, Nev., Sept. 9 /PRNewswire-FirstCall/ --
PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced that NASDAQ has established September 13, 2010 as the ex-dividend date for its second of two special dividends to stockholders declared by the Board of Directors on January 27, 2010. The dividend of $0.50 per share will be paid on October 1, 2010 to all stockholders of record on September 15, 2010.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com
PDL BioPharma to Present at Upcoming Investor Conferences
Press Release Source: PDL BioPharma, Inc.
Wednesday September 8, 2010, 7:00 am EDT
http://finance.yahoo.com/news/PDL-BioPharma-to-Present-at-prnews-931969264.html?x=0&.v=1
INCLINE VILLAGE, Nev., Sept. 8 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced that John P. McLaughlin, the Company's president and chief executive officer, will present at the following upcoming conferences.
Rodman & Renshaw Annual Global Investment Conference
Monday, September 13, 2010
4:30 p.m. Eastern time
New York City
Morgan Stanley Global Healthcare Unplugged Conference
Tuesday, September 14, 2010
3:55 p.m. Eastern time
New York City
Both presentations will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.
Coverage initiated on PDL BioPharma by RBC Capital Mkts
Upgrades & Downgrades History
http://finance.yahoo.com/q/ud?s=PDLI
10-Sep-10 Initiated RBC Capital Mkts Sector Perform $6
http://www.finviz.com/quote.ashx?t=pdli&ty=c&ta=0&p=d
Cardium Announces Appexium(TM), a New Weight Loss Management Dietary Supplement to Expand MedPodium's Healthy Lifestyle Product Initiative
09.09.2010 15:33
http://www.finanznachrichten.de/nachrichten-2010-09/17918356-cardium-announces-appexium-tm-a-new-weight-loss-management-dietary-supplement-to-expand-medpodium-s-healthy-lifestyle-product-initiative-008.htm
SAN DIEGO, Sept. 9 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the addition of a new weight management product, Appexium(TM), to Cardium's MedPodium(TM) product line. Appexium, a plant-derived non-prescription dietary supplement to be marketed under the trade name Linee(TM), is designed to manage weight by lowering appetite and hunger in order to reduce caloric intake and facilitate weight loss. Cardium is planning to formally launch its MedPodium product line in October. The addition of Appexium represents an important step toward broadening the Company's advanced skin care line to include additional healthy lifestyle medicinals.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
Appexium, taken orally an hour before meals and snacks, is designed to physiologically send a satiety signal to the brain to effectively reduce appetite. Appexium's active ingredient is a highly-concentrated extract from white potato, standardized to Proteinase Inhibitor-II (PI-2), that promotes the release cholecystokinin (CCK), a natural peptide hormone secreted by the small intestine and released into the blood stream. CCK is a well-researched peptide that is believed to play an important role in modulating appetite and hunger. Appexium's custom formulation contains a blend of PI-2, vitamin D and vitamin B-12, which is filled into small, easy swallow, pharmaceutical-quality capsules. Appexium may be used as a stand-alone product, integrated as part of exercise, yoga and other fitness programs, or used in concert with popular weight-loss and dietary meal plan programs to enhance plan compliance and improve results.
"We are pleased to announce the addition of Appexium to our MedPodium lifestyle medicinal brand initiative. Following our planned launch of the MedPodium product platform in October, which will initially include seven podiatry-focused advanced skin care products and Appexium, we plan to further broaden and expand our MedPodium brand initiative to encompass other lifestyle medicinals that may include neurologics, metabolics and aesthetics designed to address emerging lifestyle issues for highly-targeted market segments. Our products will initially be available through Cardium's MedPodium web-based boutique. Following market launch we also plan to market and sell certain products through various select distributors or retailers in the United States," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.
About Appexium
Appexium is a dietary supplement based on the use of Proteinase Inhibitor-II (PI-2), a naturally-occurring protein derived from white potato that is a commonly consumed food and generally recognized as safe. While extracted and concentrated, PI-2 is not altered chemically. It is designed to physiologically send a satiety signal to the brain in order to reduce appetite and hunger. Its mechanism of action does not rely on absorbing fat or causing fullness or bloating in the gastrointestinal (GI) tract as in many other weight loss aids and dietary supplements that are sometimes not well tolerated due to discomfort, GI bloating and irregular bowel discharge. Based on independent clinical studies, Appexium's active ingredient promotes the release of clinically meaningful levels of cholecystokinin (CCK) that may increase feelings of fullness and therefore help to reduce the amount of food eaten daily.(1)(2) While exercise is important, years of research has suggested that the most effective means of ensuring weight loss in the average healthy person is by reducing total daily caloric intake. The CCK satiety mechanism of action has been well researched. Based on a multi-site, randomized, double-blind, controlled clinical study, patients receiving the PI-2 active ingredient, twice daily before the two largest meals, had statistically significant reductions in overall weight as well as in waist and hip measurements, as compared to placebo.(3)
About MedPodium
The MedPodium product line initially included seven podiatry-focused advanced skin care products designed to promote health and comfort and support preventative care, self examination and early detection of foot ulcers, especially for diabetic patients with lower extremity neuropathy. The MedPodium podiatry-focused skin care products have been formulated to include blended natural and botanical ingredients, and have no artificial colors and fragrances. The various products contain exfoliants to promote the release of dead skin cells and stimulate the production of new skin cells, natural vitamin antioxidants, as well as other nutrient-rich elements to promote soft, supple and healthy skin. The addition of Appexium further broadens and expands Cardium's in-house MedPodium brand initiative to encompass other healthy lifestyle medicinals.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform. The Company's lead product candidates include: (1) Excellagen(TM) topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx®, a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MedPodium product platform will be commercially successful or will effectively enhance our businesses or their market value, that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, that Appexium or our other products will prove to be sufficiently safe and effective after introduction into a broader patient population, that the FTC will accept the clinical studies cited in this release as substantiation for the product claims; that results or trends observed in clinical studies or other observations will be reproduced in subsequent studies or in broader use, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other health regulatory agencies will not introduce additional or more restrictive regulations covering naturally-derived products such as those in our MedPodium product line, that our in-house or external product commercialization efforts will be successful or will effectively enhance our businesses or their market value, or that any of the third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of biologics and in the conduct of human clinical trials and other product development efforts, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition and regulation, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
1. Badman, MK, Flier, JS. The Gut and Energy Balance: Visceral Allies in the Obesity Wars. (2005) Science. 307: 1909-1914 2. Hu, J, Edmonson B, Radosevich J. The effectiveness of potato proteinase inhibitor II in promoting satiety in healthy human subjects: VAS summary. Kemin Consumer Care White Paper. 2004 3. Dana, S. A randomized, double-blind, placebo-controlled clinical study demonstrates Slendesta potato extract is a safe and effective tool for promoting weight reduction. Kemin Consumer Literature
Note: The statements in this press release have not been evaluated by the Food and Drug Administration. Appexium is not intended to diagnose, treat, cure or prevent any disease.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/.
Cardium Therapeutics(TM) Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM), Osteorate(TM), Appexium(TM) and Linee(TM)are trademarks of Tissue Repair Company. (Other trademarks belong to their respective owners)
Photo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO
Cardium Therapeutics
CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., +1-858-436-1018, InvestorRelations@cardiumthx.com
Web Site: http://www.cardiumthx.com/
© 2010 PR Newswire
Cardium to Present at the Rodman & Renshaw 12th Annual Healthcare Investment Conference
09.09.2010 15:30
http://www.finanznachrichten.de/nachrichten-2010-09/17918320-cardium-to-present-at-the-rodman-renshaw-12th-annual-healthcare-investment-confe
SAN DIEGO, Sept. 9 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the Rodman&Renshaw 12th Annual Healthcare Investment Conference on September 14, 2010 at 4:55 p.m. Eastern Time. The conference, which will feature more than 500 presenting companies and 3,500 attendees, is being held September 12-15, 2010 at the New York Palace Hotel in New York. A webcast of the Company's presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq18/cxm/ or the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar. The investor presentation slides are available and can be viewed at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/. Cardium Therapeutics(TM) and Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM)are trademarks of Tissue Repair Company.
Photo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
AP Archive: http://photoarchive.ap.org/
http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO
PRN Photo Desk, photodesk@prnewswire.com
Cardium Therapeutics
CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., +1-858-436-1018, InvestorRelations@cardiumthx.com
Web Site: http://www.cardiumthx.com/
© 2010 PR Newswire
Dahlman Rose & Co. to Host 3rd Annual Global Transportation Conference
NEW YORK, Sept. 1 /PRNewswire/ -- Leading railroad, trucking and aircraft leasing company executives will be presenting at Dahlman Rose & Co.'s Third Annual Global Transportation Conference on September 8-9, 2010 at the St. Regis Hotel in New York City. Dahlman Rose & Co. is a leading investment bank specializing in natural resources, transportation and other industries in the global supply chain.
The two-day conference will consist of presentations led by executives from the following public companies:
RAIL – Canadian National Railway (NYSE:CNI - News); Canadian Pacific (NYSE:CP - News); CSX Corporation (NYSE:CSX - News); Genesee & Wyoming (NYSE:GWR - News); Kansas City Southern (NYSE:KSU - News); Norfolk Southern Corporation (NYSE:NSC - News); and RailAmerica (NYSE:RA - News).
TRUCKING – Arkansas Best Corporation (Nasdaq:ABFS - News); Celadon Group (NYSE:CGI - News); Con-way (NYSE:CNW - News); Knight Transportation (NYSE:KNX - News); Landstar System (NASDAQ:LSTR - News); Old Dominion Freight Line (Nasdaq:ODFL - News); Saia (Nasdaq:SAIA - News); Vitran Corporation (Nasdaq:VTNC - News); Werner Enterprises (Nasdaq:WERN - News); and YRC Worldwide (Nasdaq:YRCW - News).
Aircraft leasing, shipping, private shortline railroad and logistics company executives will also be participating in panels during the conference to provide investors with their outlook on the industry.
"This event will provide institutional investors with valuable access to top executives of leading transportation companies," said Simon Rose, Chief Executive Officer of Dahlman Rose & Co. "Our conference will highlight current market dynamics as well as future trends with a focus on the critical relationship between the global transportation industry and the overall economy."
Jason Seidl, Dahlman Rose's Rail & Trucking research analyst, stated, "We are pleased to continue our tradition of sponsoring a conference that fosters an in-depth discussion between institutional investors and major freight transportation providers. With a comprehensive agenda comprised of company presentations, one-on-one meetings and panel discussions, this event offers a unique opportunity for investors to expand their network and further their industry knowledge."
For further details and an agenda regarding Dahlman Rose & Co.'s 3rd Annual Global Transportation Conference, please contact Dahlman Rose representatives Michelle Becker at 212-920-2991 or Halle Petro at 212-702-4509. They can also be reached via email at events@dahlmanrose.com.
Press Release Source: Dahlman Rose & Co., LLC
September 1, 2010, 8:30 am EDT
http://finance.yahoo.com/news/Dahlman-Rose-Co-to-Host-3rd-prnews-1701439096.html?x=0
Quantum to Showcase StorNext 4.0 Software Enabling End-to-End Digital Workflow in Live Demonstration at IBC 2010
Date : 09/07/2010 @ 4:05PM
Source : MarketWire
Stock : Quantum Corporation (QTM)
http://ih.advfn.com/p.php?pid=nmona&article=44277191&symbol=QTM
Quantum Corp. (NYSE: QTM), the leading global specialist in backup, recovery and archive, today announced that it will conduct live demonstrations of a broadcast workflow and tiered storage environment enabled by the company's StorNext 4.0 data management software at IBC 2010. Designed to meet the challenges of tremendous rich media growth resulting from new 3-D and HD technologies, StorNext 4.0 software provides real-time, high-performance access, sharing, management, tiering and archiving of media files to optimize and speed production of final content. Also at the conference, Quantum will highlight its Scalar i6000 enterprise library with LTO-5 tape. Working with StorNext®, the Scalar i6000 gives broadcasters an intelligent and cost-effective tiered storage and archiving solution for long-term content retention and protection. With new Media Data Integrity Analysis (MeDIA) functionality in the Scalar i6000, broadcasters can be assured that their content is maintained at the highest levels of dependability required for media archives.
The StorNext 4.0 demonstration will show how it enables the specialized requirements of broadcast workflows whilst at the same time using well known industry applications running on standard hardware platforms.
Multiple Quantum partners will also be using StorNext to enable their demonstrations at the show.
Both the StorNext and Scalar i6000 products will be on display in Quantum's booth (Hall 7, Stand G27), September 10-14, at the RAI Centre in Amsterdam.
StorNext 4.0
In addition to its high-performance access, sharing and archiving capabilities, StorNext 4.0 boasts several new features for the media and entertainment industry, including partial file retrieval, replication and distributed data movers. For active archiving purposes, StorNext 4.0 provides media-aware, timecode-based Partial File Retrieval (PFR) to streamline workflow in media asset management applications. Operating in real time, PFR allows segments of large media files -- rather than the entire file -- to be quickly retrieved and utilized based on timecode parameters.
The new robust replication engine provides many options for protecting and managing data across distributed environments. Broadcasters can adopt a data distribution strategy to achieve a 24/7 global workflow, reducing project timelines and cost. In addition, with its deduplication functionality, StorNext 4.0 can intelligently replicate only unique data, thereby significantly reducing network bandwidth and storage requirements.
Finally, new distributed data movers (DDMs) deliver added performance to StorNext's Storage Manager™ archiving software by enabling faster access to content that has been archived to tape as part of a cost-efficient tiered storage strategy.
Scalar i6000
The Scalar i6000, introduced in April, is Quantum's new tape library built for large-scale environments. It can hold up to 5300 cartridges, enabling storage of 8 PB of media files or the equivalent of 2,000 hours of 4K HD video. With new security and failover features and greater capacity and performance improvements resulting from the integration of LTO-5 tape drives, the Scalar i6000 also saves significant floor space and lowers power and cooling costs.
The Scalar i6000 incorporates Quantum's next-generation iLayer™ software with an innovative new archiving and management feature called Media Data Integrity Analysis (MeDIA). This feature is ideal for checking the restore capabilities of archived or deep vaulted content stored on tape. It can proactively scan thousands of archived cartridges to detect potential data problems and maintain integrity. MeDIA provides three levels of media scanning and runs in the background so it does not affect day-to-day operations.
About Quantum
Quantum Corp. (NYSE: QTM) is the leading global storage company specializing in backup, recovery and archive. Combining focused expertise, customer-driven innovation, and platform independence, Quantum provides a comprehensive, integrated range of disk, tape, and software solutions supported by a world-class sales and service organization. This includes the DXi™-Series, the first disk backup solutions to extend the power of data deduplication and replication across the distributed enterprise. As a long-standing and trusted partner, the company works closely with a broad network of resellers, OEMs and other suppliers to meet customers' evolving data protection needs. Quantum Corp., 1650 Technology Drive, Suite 800, San Jose, CA 95110, (408) 944-4000, www.quantum.com.
Quantum, the Quantum logo, Scalar and StorNext are registered trademarks of Quantum Corporation and its affiliates. DXi, iLayer and StorNext Storage Manager are trademarks of Quantum Corporation and its affiliates. All other trademarks are the property of their respective owners.
"Safe Harbor" Statement: This press release contains "forward-looking" statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Specifically, but without limitation, statements relating to 1) customer benefits and value to customers from using Quantum's StorNext 4.0 software and Scalar i6000 libraries, and 2) customer demand for and Quantum's future revenue from such software and libraries, are forward-looking statements within the meaning of the Safe Harbor. All forward-looking statements in this press release are based on information available to Quantum on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause Quantum's actual results to differ materially from those implied by the forward-looking statements. These risks include operational difficulties, unforeseen technical limitations, unexpected material deviation in product operation, the ability of competitors to introduce new solutions that compete more successfully with our solutions, unexpected changes in market conditions and unanticipated changes in customers' needs or requirements, as well as the risks set forth in Quantum's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in Quantum's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2010 and in Quantum's Annual Report on Form 10-K filed with the Securities and Exchange Commission on June 11, 2010. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact:
Jon Short
Red Lorry Yellow Lorry
+44 (0) 20 7403 8878
jons@rlyl.com
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date : 09/08/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=44286548&symbol=KERX
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following investor conferences:
Monday, September 13, 2010 – 2:00 p.m. EDT
Rodman & Renshaw 12th Annual Healthcare Conference
New York Palace Hotel
New York City
Tuesday, September 14, 2010 - 1:15 p.m. EDT
Baird's 2010 Health Care Conference
St. Regis Hotel
New York City
Wednesday, September 15, 2010 - 3:15 p.m. EDT
Stifel Nicolaus Healthcare Conference
Four Seasons Hotel
Boston, MA
A live audio webcast of Mr. Bentsur's presentations will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.
Cystic Fibrosis Phase II study has been completed
ClinicalTrials.gov processed this record on September 02, 2010
http://www.clinicaltrials.gov/ct2/show/NCT00934362?term=cystic+fibrosis&rank=136
...now you are a "free agent" - so be part of it
"Orion Labor Day Contest Pick" @ 2010 Orion Party Bashers Stocks - board
WIN 3 month free Subscription to IHUB Labor Day Contest 7-10 September 2010
Courtesy of IHUB Admin Matt
"PLEASE READ RULES BELOW"
Visit and Boardmark the board
http://investorshub.advfn.com/boards/board.aspx?board_id=12753
3 Month Free Subscription to IHUB
Rules: ONE STOCK PICK ENTRY
1.) No OTCBB or Pinkies stocks
2.) Only Stocks between $1.00 - $5.99 3.) Winner Will be determined by highest one week increase % from 7 - 10 September 2010.
4.) Post your pick- No earlier 4:01 PM Friday 3 September and no later than 11:59 PM EST Hours on September 6th, 2010.
5.) Title all messages (posts) with "Orion Labor Day Contest Pick" 6.) No one can have the same stock. First to post gets first selection.
Data-storage sales rise 20% in second quarter, says IDC
Sept. 3, 2010, 11:20 a.m. EDT
http://www.marketwatch.com/story/data-storage-sales-rise-20-in-second-quarter-2010-09-03?siteid=yhoof
By Benjamin Pimentel, MarketWatch
SAN FRANCISCO (MarketWatch) --
Sales of external data-storage systems rose 20% in the second quarter, as customers continued to invest in a critical segment of the corporate tech market, an industry group said Friday.
External data-storage revenue totaled about $5 billion in the second quarter, up 20.4% from the year-earlier period, according to IDC. The market also grew 18.6% year-over-year in the first half of the year, the group said.
...
Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe
Date : 09/01/2010 @ 8:42AM
Source : PR Newswire
Stock : Unilife (MM) (UNIS)
http://ih.advfn.com/p.php?pid=nmona&article=44205517&symbol=N^UNIS
Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that its Unitract™ Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
The Unitract™ TB syringe is a variant of the Unitract™ 1mL Insulin Syringe for which Unilife secured FDA clearance earlier this year. Unlike insulin syringes which are primarily used by people with diabetes, TB syringes are used for the administration of a range of therapeutic drugs and vaccines within acute-care hospitals and other healthcare facilities.
The Unitract™ range of 1mL syringes is the world's first and only known syringe that allows operators to control the speed of passive (automatic) needle retraction directly from the patient's body into the barrel of the syringe where it is locked in place. The products are well positioned to help prevent the transmission of blood-borne diseases such as HIV and hepatitis C via needlestick injuries, aerosol dispersal and syringe reuse. Primary target markets of the products include healthcare facilities, pharmaceutical companies and patients who self-administer prescription medication. Production of the Unitract™ 1mL syringe is occurring at Unilife's FDA-registered manufacturing facility in Lewisberry, Pennsylvania.
Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "U.S. FDA 510k market clearance for our Unitract™ TB syringe marks an important step in our company's efforts to bring a complete line of safety syringes to market, as it is our second product to receive this clearance. With TB syringes most commonly used within acute-care hospitals and other healthcare facilities, FDA clearance of our Unitract™ TB syringe significantly broadens our capacity to market our unique products across the U.S. and other key international markets."
Unilife has also recently secured its EC certification to apply the CE Mark to its Unitract™ 1mL syringes manufactured at its Lewisberry facility, allowing the sale and distribution of these products within the European Union and Australia.
The Company also expects to complete studies required to attain a five-year shelf life expiration date for its full range of Unitract™ 1mL syringes in September. The inclusion of a five-year expiry date on medical device packaging is considered to be the gold-standard within the industry, and should help to finalize discussions with a number of interested U.S. healthcare distributors in the near future.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.
Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
Date : 08/30/2010 @ 4:05PM
Source : PR Newswire
Stock : Unilife (MM) (UNIS)
http://ih.advfn.com/p.php?pid=nmona&article=44180016&symbol=N^UNIS
PR Newswire
LEWISBERRY, Pa., Aug. 30
LEWISBERRY, Pa., Aug. 30 /PRNewswire-FirstCall/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced preliminary financial results for the fourth quarter and fiscal year ended June 30, 2010.
Mr. Alan Shortall, Chief Executive Officer of Unilife said: "Fiscal 2010 has been a pivotal year for Unilife, as we completed several major milestones including the redomiciliation of the Company to the U.S. and our listing on NASDAQ."
"We have also expanded our executive team and board of directors to reflect our U.S. expansion. Each person brings to the company specific skills and experience that will help guide us through what we expect to be an extremely busy and exciting next couple of years."
"We are now working to finalize the industrialization of the Unifill™ syringe and expand relationships with interested pharmaceutical companies, accelerate the global rollout of our Unitract 1mL syringes; and complete the construction of our new state-of-the-art facility in York, Pennsylvania. We remain committed to the continued implementation of our business strategy, and the execution of a number of significant business milestones during fiscal 2011."
Annual Company Highlights:
* Redomiciled the Company to the U.S. (January 2010).
* Unilife Corporation common stock listed on the NASDAQ stock exchange (February 2010).
* Signed an industrialization agreement with sanofi-aventis (July 2009), followed by an agreement between both parties to a list of therapeutic classes including vaccines and anti-thrombotic agents where sanofi-aventis has exclusive rights to negotiate the purchase of the Unifill syringe until June 2014 (March 2010).
* Appointed the Mikron Group as the contracted supply partner for the development and supply of automated assembly systems to support the commercial production of the Unifill™ syringe (November 2009).
* Initiated U.S. production of the Unitract 1mL Insulin Syringe in Lewisberry, Pennsylvania (PA) (August 2009), and the subsequent first shipment of the product to Doctors Without Borders to support relief efforts in Haiti.
* Received U.S. FDA market clearance for the Unitract 1mL Insulin Syringes assembled in Lewisberry, PA (April 2010), and the provision of EC certification for the European Union and Australia (June 2010).
* Signed distribution agreements for the Unitract 1mL syringes, including an agreement with Stason Pharmaceuticals Inc for Japan, China and Taiwan (March 2010); and an agreement with Clinicare for India (April 2010).
* Started construction on new global headquarters and commercial production facility in York, PA (December 2009). The new 165,000 square foot state-of-the-art facility is on schedule for operations by late-2010.
* Following the signing of the Industrialization Agreement, Unilife was able to commence discussions with other pharmaceutical companies interested in the use of the Unifill™ syringe within therapeutic drug classes outside of those retained by sanofi-aventis. A number of these discussions have accelerated during the past year.
* Appointed additional U.S. based Board members, including Mary Kate Wold, Marc Firestone and John Lund, as well as the appointment of senior executives including CFO and Executive Vice President Richard Wieland and General Counsel, Corporate Secretary and Chief Compliance Officer Chris Naftzger.
Preliminary Financial Results for Fourth Quarter and Fiscal Year Ended June 30, 2010
Revenues for the fourth quarter ended June 30, 2010 were $2.7 million compared to $7.7 million for the same period in 2009. Revenues for the fiscal year ended June 30, 2010 were $11.4 million compared to $20.0 million for the same period in 2009. The decrease was primarily attributable to a relative decline in revenues from the Company's industrialization agreement with sanofi-aventis in 2010, due to the accelerated receipt of milestone payments during 2009 because the industrialization program was running ahead of its original schedule. The Company has elected to prioritize its activities on the development and supply of its proprietary range of safety syringes. It has consequently reduced its business activities within the medical device contract manufacturing sector during this period.
The Company's net loss for the fourth quarter ended June 30, 2010 was $9.7 million or $0.18 per diluted share, compared to net income of $2.2 million, or $0.06 per diluted share for the same period in 2009. The Company's net loss for the fiscal year ended June 30, 2010 was $29.7 million or $0.64 per diluted share, compared to a net loss of $0.5 million, or $0.02 per diluted share for the same period in 2009. The increase in the net loss was attributable to both the decline in revenues as well as higher payroll and related expenses due to an increase in the workforce at the Lewisberry, PA facility. The Company also incurred an increase in legal and consulting fees in connection with its redomiciliation to the United States.
Adjusted net loss for the fourth quarter ended June 30, 2010, which excludes approximately $4.0 million in share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $5.7 million, or $0.11 per diluted share compared to adjusted net income of $3.0 million or $0.08 per diluted share for the same period in 2009. Adjusted net loss for the fiscal year ended June 30, 2010, which excludes approximately $15.2 million in share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $14.5 million, or $0.31 per diluted share compared to adjusted net income of $3.9 million or $0.11 per share for the same period in 2009.
As of June 30, 2010, the Company's cash and cash equivalents were $20.8 million.
The financial data included in this press release is based on preliminary unaudited information and may be subject to change. The Company expects to file its audited results for the fiscal year ended June 30, 2010 on Form 10-K with the Securities and Exchange Commission on September 28, 2010.
Conference Call Information
Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Daylight Time on August 30, 2010, to review the Company's financial results, market trends and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in other reports which we file with the Securities and Exchange Commission.
...
NewCardio CEO Increases Equity Position
Date : 09/02/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=44221591&symbol=NWCI
NewCardio (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, today announced that Vincent Renz, Jr., NewCardio's President and CEO, purchased 128,000 shares during his trading window in open market transactions in the two weeks following the Company's filing of its SEC Form 10-Q and earnings conference for the second quarter ended June 30, 2010.
"As discussed on our August 12, 2010 investor conference call, we are focused on the underlying fundamentals that will enable us to create long term value for our employees, customers and shareholders," commented Mr. Renz. "We continue to make steady progress with the commercialization of QTinno™ as our efforts to enhance market awareness and adoption through our interactions with clinical trial service providers, sponsors and regulatory authorities are starting to translate into increasing sales opportunities which we believe will drive revenue growth and expansion. In addition, we are working to identify opportunities, either through strategic partnerships or other relationships, to source additional capital that will enable us to accelerate the development and commercialization of our proven 3-D platform technology in delivering additional solutions which will advance the ECG as a diagnostic tool."
Mr. Renz continued, "Specifically, the additional capital will be focused on the commercialization of our second and third products, CardioBip™ and Cardio3KG™. Based on the progress we have made in the development and validation efforts to date, as well as the size of the potential markets that these solutions will address, I do not believe the market has appropriately valued NewCardio, for either our achievements to date or the potential of our underlying 3-D technology platform. My recent purchases demonstrate my confidence in our ability to create long term value and reinforce my long-term commitment to helping the Company maximize its chances for success."
In conjunction with the December 2007 $8.2 million PIPE financing, on August 27, 2010, several early investors, including select members of the board of directors, pursuant to lock-up agreements they delivered to facilitate the PIPE financing, entered a lock-up period whereby they cannot sell any NewCardio stock for the one year through August 27, 2011. This group represents more than one-third of the approximately 30 million shares of common stock outstanding. In anticipation of this one year lock-up, and in conjunction with his transition from CEO and his voluntary salary reduction taken as part of the current expense reduction plan that was put in place by management to strengthen its financial position, Branislav Vajdic, Ph.D., Founder, Vice Chairman and NewCardio Fellow and one of the investors subject to the lock-up, sold 295,000 shares. The sale represents his only sale since founding the Company in 2004.
Describing the trade, Dr. Vajdic stated, "I am pleased and proud to continue to be the single largest shareholder of NewCardio, and thus believe I am fully aligned with all our shareholders. I remain committed to the success of the Company and believe that we are getting close to achieving the promise we saw when we founded the Company around our powerful 3-D technology platform to improve the value of the most widely used cardiology diagnostic tool in the world, the ECG. As part of our plan moving forward, I retain approximately 97% of my holdings and NewCardio remains my single largest personal asset. This was a limited opportunity to provide some liquidity and I remain fully committed to the success of the Company both as the Vice Chairman and a key technical expert."
In aggregate, officers and directors now beneficially own approximately 36% of the NewCardio's outstanding common stock.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio
New Quantum Deduplication Appliance With VTL Interface Offers Unique Combination of High Performance, Simplicity and Value
Date : 08/30/2010 @ 8:00AM
Source : MarketWire
Stock : Quantum Corporation (QTM)
http://ih.advfn.com/p.php?pid=nmona&article=44175737&symbol=NY^QTM
Quantum Corp. (NYSE: QTM), the leading global specialist in backup, recovery and archive, today announced a new deduplication and replication appliance that leverages a VTL interface to offer midrange and enterprise customers an unmatched combination of performance, simplicity and value for Fibre Channel SAN environments. The DXi6700 delivers up to 3.5 TB per hour backup performance and provides up to 56 TB of usable capacity. The turnkey appliance comes with all licensed software features bundled at purchase, including both replication and direct tape creation. This approach gives customers a low-cost, easy-to-implement deduplication solution that works effectively with all leading backup applications, providing both multi-site and multi-tier data protection. In addition, the DXi6700 incorporates Quantum's new Advanced Reporting tools for improved resource utilization and ease of management.
"The DXi6700 adds to Quantum's DXi6000 models of purpose-built deduplication and replication appliances, following last year's introduction of the NAS/OST-optimized DXi6500 family for the midrange market," noted Jeff Boles, senior analyst, Taneja Group. "Combined with the launch of the DXi4500 for SMB environments in April, Quantum continues to focus on providing DXi-Series customers with a compelling combination of high performance and overall value."
High-Performance Appliance for Fibre Channel Environments
The DXi6700 provides IT departments with faster backup performance and trouble-free restores, while typically reducing disk capacity usage by 90 percent or more. Scaling from 24 TB to 56 TB usable capacity, the DXi6700 delivers enterprise-class speeds of up to 3.5 TB per hour in a platform with the simplicity and value to match midrange applications. All DXi6000 models provide advanced technology, utilizing the latest processor cores and 8Gb FC connections.
"Quantum was first to market with open systems VTL, and today our Fibre Channel deduplication systems solve demanding challenges for some of the largest organizations in the world," said Janae Lee, senior vice president, Disk and Software Products Group, Quantum. "With the DXi6700, customers get enterprise-class performance and reliability in an easy-to-use appliance that provides far greater value than competitive offerings in terms of both cost savings and benefits."
Simple and Affordable Backup and Retention with Integrated Tape Creation
The DXi6700's proven VTL interface integrates directly into existing Fibre Channel SAN environments for an easy-to-deploy disk backup solution. Its remote replication and integrated direct tape creation features provide both automated near-term disaster recovery and long-term data retention. Quantum's direct tape creation writes data from the DXi™ system to tape over a direct connection, bypassing the backup server. The operation is integrated with leading backup software to provide automation, a single point of management, and a fully synchronized catalog across disk and tape. All of this makes the DXi6700 an easily-shared backup and restore resource for all leading backup applications, offering multi-site, multi-tier protection that is simple to manage. Designed to be user-installable, the DXi6700 scales easily on-site without requiring a service visit, providing effective investment protection. It also integrates with Quantum Vision 4.0, which enables global management of Quantum disk and tape systems from a single console.
Practical Near-Term Disaster Recovery and Remote Office Protection
To address the persistent IT challenge of affordably managing disaster recovery protection for distributed sites, the DXi6700 replicates backup data between sites, using deduplication to reduce typical network bandwidth requirements by a factor of 20 or more, and encrypting data prior to transmission for security. With the DXi6700, users can reduce or even eliminate the need to manage removable media.
Advanced Reporting Tools for Onboard Intelligence
Now included standard with all DXi™-Series appliances, the Advanced Reporting tools in DXi6700 present a detailed view of internal appliance operations, including backup and replication data for flexible trend analyses, enabling smarter planning and lower long-term costs. The tools also provide insights into CPU, disk I/O and network traffic activity per port and monitor capacity utilization, reclamation and replication status. DXi Advanced Reporting cuts administration time, streamlines performance tuning, improves troubleshooting, and helps users maximize the value of their DXi-Series appliances.
"Based on our customers' experience with the DXi-Series, the DXi6700 shows great promise as a midrange deduplication appliance, with its pre-configured design and bundled software," said John Woodall, vice president of engineering, Integrated Archive Systems, Inc. "For companies seeking an easily-integrated approach to expanding a VTL backup environment, the DXi6700 will be a great fit."
Award-Winning Platform
The DXi6700 is based on the same platform as Quantum's DXi6500 family of disk backup appliances, which in June was named "Deduplication Product of the Year" at the 2010 Storage Awards: The Storries VII. The awards were based on more than 25,000 votes cast by the readers of Storage Magazine, the U.K.'s leading IT and storage publication.
Price and Availability
The DXi6700 starts at $159,000 MSRP and is available today through Quantum's channel partners.
For Additional Information
For more on the DXi6700, visit http://www.quantum.com/Products/Disk-BasedBackup/DXi6700/Index.aspx.
For a brief podcast exploring the key questions to ask before implementing deduplication, visit:
Part 1:
http://www.quantum.com/flash/TheMostImportantQuestion_podcast/Part1/Quantum_beforeYouDedupe-a_Part1.html
Part 2:
http://www.quantum.com/flash/TheMostImportantQuestion_podcast/Part2/Quantum_BeforeYouDedupe-Part2.html
About Quantum
Quantum Corp. (NYSE: QTM) is the leading global storage company specializing in backup, recovery and archive. Combining focused expertise, customer-driven innovation, and platform independence, Quantum provides a comprehensive, integrated range of disk, tape, and software solutions supported by a world-class sales and service organization. This includes the
DXi™-Series, the first disk backup solutions to extend the power of data deduplication and replication across the distributed enterprise. As a long-standing and trusted partner, the company works closely with a broad network of resellers, OEMs and other suppliers to meet customers' evolving data protection needs. Quantum Corp., 1650 Technology Drive, Suite 800, San Jose, CA 95110, (408) 944-4000, www.quantum.com.
Quantum and the Quantum logo are registered trademarks of Quantum Corporation. DXi and Quantum Vision are trademarks of Quantum Corporation. All other trademarks are the property of their respective owners.
"Safe Harbor" Statement: This press release contains "forward-looking" statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Specifically, but without limitation, statements relating to 1) customer benefits and value to customers from using Quantum's DXi6700 systems, and 2) customer demand for and Quantum's future revenue from such systems, are forward-looking statements within the meaning of the Safe Harbor. All forward-looking statements in this press release are based on information available to Quantum on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause Quantum's actual results to differ materially from those implied by the forward-looking statements. These risks include operational difficulties, unforeseen technical limitations, unexpected material deviation in product operation, the ability of competitors to introduce new solutions that compete more successfully with our solutions, unexpected changes in market conditions and unanticipated changes in customers' needs or requirements, as well as the risks set forth in Quantum's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in Quantum's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2010 and in Quantum's Annual Report on Form 10-K filed with the Securities and Exchange Commission on June 11, 2010. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Bob Wientzen
Public Relations
Quantum Corp.
(720) 406-5667
bob.wientzen@quantum.com
Industry Center - Data Storage Devices
http://biz.yahoo.com/ic/813.html
Quantum Wins "Deduplication Product of the Year" and "Best Tape Product" at UK 2010 Storage Awards
The Storries VII Recognise Quantum's Midrange DXi6500 Disk Backup Family and Scalar i6000 Enterprise Tape Library
http://phx.corporate-ir.net/phoenix.zhtml?c=69905&p=irol-newsArticle&ID=1441593&highlight=
LONDON, Jun 24, 2010 (MARKETWIRE via COMTEX) --Quantum Corp. (NYSE: QTM), the leading global specialist in backup, recovery and archive, today announced that its DXi6500 family of disk backup appliances and Scalar(R) i6000 tape library were named "Deduplication Product of the Year" and "Best Tape Product," respectively, at the 2010 Storage Awards: The Storries VII. Based on more than 25,000 votes cast by the readers of Storage Magazine, the UK's leading IT and storage publication, the awards are testament to Quantum's continued commitment to excellence and innovation in solutions that meet customers' data protection requirements.
Leveraging Quantum's patented data deduplication technology, the DXi6500 family offers simplicity and value in addressing the backup challenges facing midrange customers. All five DXi6500 models include a simple NAS interface, built-in deduplication and replication, support for Symantec's OpenStorage (OST) API, and backup software for VMware environments bundled in the base price. In addition, the DXi6540 and DXi6550 provide direct tape creation.
The Scalar i6000 incorporates Quantum's next-generation iLayer(TM) software with new innovative archiving capabilities and management benefits, providing enterprise customers with a long-term archive and data retention solution optimised for the evolving role of tape in data protection.
"We would like to thank our users and peers within the storage industry for recognising not just one, but two of our leading products in this year's Storage Awards," said Gabriel Chaher, Senior Director, EMEA/APAC Product and Field Marketing at Quantum. "Following our DXi7500 enterprise backup and deduplication solution being named 'Storage Product of the Year' in 2009, these latest awards represent further validation for the strength of Quantum's disk and tape offerings in addressing customers' data protection and management needs."
For more on the DXi6500 family, visit: http://phx.corporate-ir.net/phoenix.zhtml?c=69905&p=irol-newsArticle&ID=1344481&highlight.
For more on the Scalar(R) i6000, visit: http://phx.corporate-ir.net/phoenix.zhtml?c=69905&p=irol-newsArticle&ID=1409946&highlight.
About Quantum
Quantum Corp. (NYSE: QTM) is the leading global storage company specialising in backup, recovery and archive. Combining focused expertise, customer-driven innovation and platform independence, Quantum provides a comprehensive, integrated range of disk, tape and software solutions supported by a world-class sales and service organisation. This includes the DXi(TM)-Series, the first disk backup solutions to extend the power of data deduplication and replication across the distributed enterprise. As a long-standing and trusted partner, the company works closely with a broad network of resellers, OEMs and other suppliers to meet customers' evolving data protection needs. Quantum Corp., 1650 Technology Drive, Suite 800, San Jose, CA 95110, (408) 944-4000, www.quantum.com.
Quantum, the Quantum logo and Scalar are registered trademarks of Quantum Corporation and its affiliates. DXi and iLayer are trademarks of Quantum Corporation and its affiliates. All other trademarks are the property of their respective owners.
"Safe Harbor" Statement: This press release contains "forward-looking" statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Specifically, but without limitation, statements relating to 1) customer benefits and value to customers from using Quantum's DXi6500 appliances and the Scalar i6000 tape libraries, and 2) customer demand for and Quantum's future revenue from such appliances and libraries, are forward-looking statements within the meaning of the Safe Harbor. All forward-looking statements in this press release are based on information available to Quantum on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause Quantum's actual results to differ materially from those implied by the forward-looking statements. These risks include operational difficulties, unforeseen technical limitations, unexpected material deviation in product operation, the ability of competitors to introduce new solutions that compete more successfully with our solutions, unexpected changes in market conditions and unanticipated changes in customers' needs or requirements, as well as the risks set forth in Quantum's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in Quantum's Annual Report on Form 10-K filed with the Securities and Exchange Commission on June 11, 2010. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Neil Hallmark or Clodagh Boyle
Kaizo
020 3043 4151
quantum@kaizo.net
Joanne Ayres
Quantum Corp.
01344 353 738
joanne.ayres@quantum.com
SOURCE: Quantum Corporation
Brigham Young University-Hawaii Achieves Fourfold Increase in High-Definition Video Production With Quantum StorNext
Data Management Software Enables Shared, High-Speed Workflow and Addresses Challenge of Managing Growth in Rich Media Content
Quantum Corporation On Tuesday August 24, 2010, 4:52 pm EDT
http://finance.yahoo.com/news/Brigham-Young-iw-2468612532.html?x=0&.v=1
SAN JOSE, CA--(Marketwire - 08/24/10) - Quantum Corp. (NYSE:QTM - News), the leading global specialist in backup, recovery and archive, today announced that Brigham Young University-Hawaii (BYU-Hawaii) has achieved a significant increase in video production by implementing Quantum StorNext® data management software. When the university transitioned from Standard Definition (SD) to High Definition (HD) video, its legacy infrastructure proved to be inadequate, with insufficient storage capacity and slow transfer rates. Since deploying a new SAN-based architecture that leverages StorNext software, however, BYU-Hawaii has experienced a 10x transfer speed improvement for sharing and archiving its HD videos and achieved a fourfold increase in its productivity levels.
With 2,500 students, BYU-Hawaii produces a wide variety of videos, including live broadcasts of athletic events and concerts, web streams, online classes, documentaries, promotional materials and class instruction. To help improve the quality of these videos, BYU-Hawaii made the move from SD to HD; however, the university soon realized it couldn't support HD's large files and transfer rates were suffering. For example, the university would often run out of space mid-project, and editors would need to erase video content to make room for new material. These challenges were multiplied by a complex workflow: film was captured on tape and ingested onto external hard drives using FireWire 800 before being transferred again to editing workstations.
In looking to solve these challenges, BYU-Hawaii was initially attracted to Quantum's StorNext data management software because it is compatible with Apple Final Cut Pro and ultimately chose StorNext over other solutions because of its superior integration options and scalability. The implementation and configuration took just a couple of days, and the editors experienced no disruption in their work. In conjunction with deploying StorNext, BYU-Hawaii also moved from its direct-attached storage architecture to a SAN-based system, which included two IBM DS5000 disk arrays with 28 TB of capacity, ATTO Celerity HBA adapters and a Brocade switch. Over one weekend, data was moved from existing small RAID systems and external hard drives to the new high-performance and scalable SAN infrastructure.
"We did not want to be limited by speed or capacity," says Russell T. Merrill, director of instructional media and production for BYU-Hawaii. "We have had experience with other clustered file systems, but StorNext has by far the best support safety net. In fact, StorNext is the glue that made everything work well together during the installation. It was great to eliminate the usual finger pointing between vendors as Quantum was willing to support everything we were using."
With an increase in video transfer speeds from 800 MB/sec to 8 GB/sec, StorNext has enabled multiple professionals from different fields to work simultaneously on the same file or piece of content without the previous long waits experienced as material moved through the system. StorNext has also reduced project time by a factor of four, eliminated videotape from workflow and more than doubled editing efficiency. In addition, uncompressed HD and other large file formats can now be easily transmitted through the edit bays. Every BYU-Hawaii project can be edited in HD without having to worry about space restrictions or whether the software can cope with vast amounts of storage and a large influx of users. Prior to deploying StorNext, the university's weekly shoot took two full days to complete. Now it takes only half a day, and the staff can edit as the content is transmitted to the SAN.
"By streamlining our workflow, StorNext has greatly reduced the level of stress on our user community," says Merrill. "Our experience with StorNext and working with Quantum has been terrific. We've been able to do what we had hoped to do and more, and we know we have a great partner in Quantum."
About BYU-Hawaii
Brigham Young University-Hawaii is located on the North Shore of Oahu in Laie, Hawaii. The university, founded by The Church of Jesus Christ of Latter-day Saints, was established in 1955. Today, approximately half of BYU-Hawaii's 2,500 undergraduate students come from more than 70 different countries, making it the most internationally diverse university (per capita) in the United States.
About Quantum
Quantum Corp. (NYSE:QTM - News) is the leading global storage company specializing in backup, recovery and archive. Combining focused expertise, customer-driven innovation, and platform independence, Quantum provides a comprehensive, integrated range of disk, tape, and software solutions supported by a world-class sales and service organization. This includes the
DXi™-Series, the first disk backup solutions to extend the power of data deduplication and replication across the distributed enterprise. As a long-standing and trusted partner, the company works closely with a broad network of resellers, OEMs and other suppliers to meet customers' evolving data protection needs. Quantum Corp., 1650 Technology Drive, Suite 800, San Jose, CA 95110, (408) 944-4000, www.quantum.com.
Quantum, the Quantum logo and StorNext are registered trademarks of Quantum Corporation and its affiliates. DXi is a trademark of Quantum Corporation. All other trademarks are the property of their respective owners.
"Safe Harbor" Statement: This press release contains "forward-looking" statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Specifically, but without limitation, statements relating to 1) customer benefits and value to customers from using Quantum's StorNext data management software, and 2) customer demand for and Quantum's future revenue from such software, are forward-looking statements within the meaning of the Safe Harbor. All forward-looking statements in this press release are based on information available to Quantum on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause Quantum's actual results to differ materially from those implied by the forward-looking statements. These risks include operational difficulties, unforeseen technical limitations, unexpected material deviation in product operation, the ability of competitors to introduce new solutions that compete more successfully with our solutions, unexpected changes in market conditions and unanticipated changes in customers' needs or requirements, as well as the risks set forth in Quantum's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in Quantum's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2010 and in Quantum's Annual Report on Form 10-K filed with the Securities and Exchange Commission on June 11, 2010. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Contact:
Alice Borda
Public Relations
Quantum Corp.
(408) 944-6727
alice.borda@quantum.com
Idera Pharmaceuticals, Inc. ( IDRA )
Idera Pharmaceuticals Announces Issuance of New Patents for Its Toll-like Receptor-Targeted Compounds
Date : 07/08/2010 @ 7:35AM
Source : Business Wire
Stock : Idera Pharmaceuticals, Inc. (IDRA)
http://ih.advfn.com/p.php?pid=nmona&article=43528683&symbol=N^IDRA
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
Date : 08/27/2010 @ 9:20AM
Source : Business Wire
Stock : Idera Pharmaceuticals, Inc. (IDRA)
http://ih.advfn.com/p.php?pid=nmona&article=44162962&symbol=N^IDRA
- Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer -
http://www.finviz.com/quote.ashx?t=idra&ty=c&ta=0&p=d
http://www.iderapharma.com/development/pipeline_chart.php
http://finance.yahoo.com/q/ks?s=IDRA+Key+Statistics
>> http://investorshub.advfn.com/boards/board.aspx?board_id=12385
>> http://investorshub.advfn.com/boards/board.aspx?board_id=11828
Idera Pharmaceuticals, Inc. ( IDRA )
Idera Pharmaceuticals Announces Issuance of New Patents for Its Toll-like Receptor-Targeted Compounds
Date : 07/08/2010 @ 7:35AM
Source : Business Wire
Stock : Idera Pharmaceuticals, Inc. (IDRA)
http://ih.advfn.com/p.php?pid=nmona&article=43528683&symbol=N^IDRA
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
Date : 08/27/2010 @ 9:20AM
Source : Business Wire
Stock : Idera Pharmaceuticals, Inc. (IDRA)
http://ih.advfn.com/p.php?pid=nmona&article=44162962&symbol=N^IDRA
- Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer -
http://www.finviz.com/quote.ashx?t=idra&ty=c&ta=0&p=d
http://www.iderapharma.com/development/pipeline_chart.php
http://finance.yahoo.com/q/ks?s=IDRA+Key+Statistics
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7854244
Idera Pharmaceuticals Incorporated
IDRA | 8/27/2010 9:20:00 AM
- Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer --
CAMBRIDGE, Mass., Aug 27, 2010 (BUSINESS WIRE) --
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux(R)) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN). Under the terms of the agreement, Idera is entitled to receive a payment of EUR3.0 million (approximately $3.8 million) from Merck KGaA.
"We are very pleased that Merck KGaA has initiated a clinical trial to evaluate IMO-2055 in the first-line treatment of patients with head and neck cancer," said Tim Sullivan, Ph.D., Idera's Vice President of Development Programs and Alliance Management. "The first-line trial is in addition to the Phase 2 clinical trial announced earlier this year to evaluate IMO-2055in second-line treatment of patients with recurrent or metastatic SCCHN."
About the Collaboration
Idera Pharmaceuticals entered into a worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany in December 2007 for the research, development and commercialization of Idera's Toll-like Receptor 9 (TLR9) agonists, including IMO-2055, for the potential treatment of cancers. In addition to the clinical study announced today, under the company's collaboration with Merck KGaA, IMO-2055 is being evaluated in a Phase 2 clinical trial in combination with Erbitux(R) in second-line patients with recurrent or metastatic SCCHN, in a Phase 1b clinical trial in combination with erlotinib (Tarceva(R)) and bevacizumab (Avastin(R)) in patients with advanced non-small cell lung cancer and in a Phase 1b clinical trial in combination with Erbitux(R) and an irinotecan-containing treatment regimen in patients with colorectal cancer.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.